Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 14/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19660302 | 1.00 | DPP4 (0.39) | DPP4DPP8DPP9TSHRDPP7 | |
| SCHEMBL7779225 | 0.80 | DPP4 (0.43) | DPP4DPP8DPP9TSHRDPP7 | |
| SCHEMBL5987142 | 0.80 | TSHR (0.42) | DPP4DPP8DPP9TSHRDPP7 | |
| SCHEMBL7603101 | 0.80 | TSHR (0.42) | DPP4DPP8DPP9TSHRDPP7 | |
| SCHEMBL5986125 | 0.80 | TSHR (0.42) | DPP4DPP8DPP9TSHRDPP7 | |
| SCHEMBL7779224 | 0.80 | DPP4 (0.43) | DPP4DPP8DPP9TSHRDPP7 | |
| SCHEMBL21105595 | 0.80 | DPP4 (0.43) | DPP4DPP8DPP9TSHRDPP7 | |
| SCHEMBL17833081 | 0.79 | DPP4 (0.37) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL17833218 | 0.79 | DPP4 (0.37) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL17833083 | 0.79 | DPP4 (0.37) | DPP4DPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170342064-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342064-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER | MPST, TK1, BRCA1 | DPP4 1353/4885DPP8 1176/4885DPP9 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.